CSF and plasma biomarkers in cerebral amyloid angiopathy: a single-center study and a systematic review/meta-analysis
Introduction: There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients co...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
June 13, 2024
|
| In: |
European stroke journal
Year: 2025, Jahrgang: 10, Heft: 1, Pages: 278-288 |
| ISSN: | 2396-9881 |
| DOI: | 10.1177/23969873241260538 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1177/23969873241260538
|
| Verfasserangaben: | Aikaterini Theodorou, Ioanna Tsantzali, Maria-Ioanna Stefanou, Simona Sacco, Aristeidis H Katsanos, Ashkan Shoamanesh, Theodoros Karapanayiotides, Ioanna Koutroulou, Polyxeni Stamati, David J Werring, Charlotte Cordonnier, Lina Palaiodimou, Christina Zompola, Efstathios Boviatsis, Lampis Stavrinou, Frantzeska Frantzeskaki, Thorsten Steiner, Andrei V Alexandrov, Georgios P Paraskevas and Georgios Tsivgoulis |
| Zusammenfassung: | Introduction: There are limited data regarding cerebrospinal fluid (CSF) and plasma biomarkers among patients with Cerebral Amyloid Angiopathy (CAA). We sought to investigate the levels of four biomarkers [β-amyloids (Aβ42 and Aβ40), total tau (tau) and phosphorylated tau (p-tau)] in CAA patients compared to healthy controls (HC) and patients with Alzheimer Disease (AD). - Patients and methods: A systematic review and meta-analysis of published studies, including also a 5 year single-center cohort study, with available data on CSF and plasma biomarkers in symptomatic sporadic CAA versus HC and AD was conducted. Biomarkers’ comparisons were investigated using random-effects models based on the ratio of mean (RoM) biomarker concentrations. RoM < 1 and RoM > 1 indicate lower and higher biomarker concentration in CAA compared to another population, respectively. - Results: We identified nine cohorts, comprising 327 CAA patients (mean age: 71 ± 5 years; women: 45%) versus 336 HC (mean age: 65 ± 5 years; women: 45%) and 384 AD patients (mean age: 68 ± 3 years; women: 53%) with available data on CSF biomarkers. CSF Aβ42 levels [RoM: 0.47; 95% CI: 0.36-0.62; p < 0.0001], Aβ40 levels [RoM: 0.70; 95% CI: 0.63-0.79; p < 0.0001] and the ratio Aβ42/Aβ40 [RoM: 0.62; 95% CI: 0.39-0.98; p = 0.0438] differentiated CAA from HC. CSF Aβ40 levels [RoM: 0.73; 95% CI: 0.64-0.83; p = 0.0003] differentiated CAA from AD. CSF tau and p-tau levels differentiated CAA from HC [RoM: 1.71; 95% CI: 1.41-2.09; p = 0.0002 and RoM: 1.44; 95% CI: 1.20-1.73; p = 0.0014, respectively] and from AD [RoM: 0.65; 95% CI: 0.58-0.72; p < 0.0001 and RoM: 0.64; 95% CI: 0.57-0.71; p < 0.0001, respectively]. Plasma Aβ42 [RoM: 1.14; 95% CI: 0.89-1.45; p = 0.2079] and Aβ40 [RoM: 1.07; 95% CI: 0.91-1.25; p = 0.3306] levels were comparable between CAA and HC. - Conclusions: CAA is characterized by a distinct CSF biomarker pattern compared to HC and AD. CSF Aβ40 levels are lower in CAA compared to HC and AD, while tau and p-tau levels are higher in CAA compared to HC, but lower in comparison to AD patients. |
|---|---|
| Beschreibung: | Gesehen am 02.12.2024 |
| Beschreibung: | Online Resource |
| ISSN: | 2396-9881 |
| DOI: | 10.1177/23969873241260538 |